Double Bond Pharmaceutical International AB: Double Bond Pharma signs agreement for distribution of Pharysol
Double Bond Pharmaceutical (DBP) and Vitro-Bio have today signed an agreement for distribution of Pharysol in Sweden, Norway and Denmark. The distribution will be held through Drugsson AB.
"In line with our goal to build a self-sustaining pharmaceutical company with a balanced portfolio consisting of both innovative development products and ready-to-sell unique products we are very pleased to be able to expand our collaboration with Vitro-Bio in terms of distribution of broader line of their products. Pharysol is a treatment against common cold and expected to bring the largest revenue of all current Drugsson’s products."
Pharysol is expected to generate first income in Q1 2019.
More about Pharysol: http://www.vitrobio.com/topical-viral-infection/throat-infection-2/
More about Vitro-Bio: http://www.vitrobio.com/
This information is information that Double Bond Pharmaceutical International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 12 April 2018.For more info, contact Igor Lokot, CEO Homepage: http://www.doublebp.com/ E-mail: firstname.lastname@example.org Blog: http://blog.doublebp.com Follow us on LinkedIn (https://www.linkedin.com/company/double-bond-pharmaceutical?trk=co-feed-likes-one), Facebook (https://www.facebook.com/DoubleBondPharma/) and Twitter (https://twitter.com/DoubleBondPharm)!Information on Double Bond Pharmaceutical International AB DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company's own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.